Cortexyme, Inc. (CRTX): Price and Financial Metrics


Cortexyme, Inc. (CRTX)

Today's Latest Price: $48.83 USD

0.55 (1.14%)

Updated Oct 22 4:00pm

Add CRTX to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 384 in Biotech

See all "A" rated Strong Buy stocks

CRTX Stock Price Chart Interactive Chart >

Price chart for CRTX

CRTX Price/Volume Stats

Current price $48.83 52-week high $73.84
Prev. close $48.28 52-week low $20.14
Day low $47.40 Volume 41,200
Day high $49.39 Avg. volume 132,254
50-day MA $48.04 Dividend yield N/A
200-day MA $47.13 Market Cap 1.44B

Cortexyme, Inc. (CRTX) Company Bio


Cortexyme, Inc. is a clinical stage biopharmaceutical company pioneering a novel disease-modifying therapeutic approach to treat a key underlying cause of Alzheimer’s and other degenerative diseases.


CRTX Latest News Stream


Event/Time News Detail
Loading, please wait...

CRTX Latest Social Stream


Loading social stream, please wait...

View Full CRTX Social Stream

Latest CRTX News From Around the Web

Below are the latest news stories about Cortexyme Inc that investors may wish to consider to help them evaluate CRTX as an investment opportunity.

Cortexyme Announces Issuance of Composition of Matter Patent for Atuzaginstat by the U.S. Patent and Trademark Office

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering potential therapeutics for Alzheimer’s and other degenerative diseases, announced today that the U.S. Patent and Trademark Office ("USPTO") issued U.S. Patent No. 10,730,826 relating to Cortexyme’s lead small molecule, atuzaginstat (COR388). Cortexyme's ‘826 patent provides additional composition of matter protection for atuzaginstat and gingipain inhibitors, with

Business Wire | August 27, 2020

Cortexyme EPS beats by $0.04

Cortexyme (CRTX): Q2 GAAP EPS of -$0.60 beats by $0.04.Cash, cash equivalents, and short and long-term marketable securities of $210.6MPress Release...

Seeking Alpha | August 17, 2020

Cortexyme Announces Second Quarter 2020 Financial Results and Provides Business Update

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering potential therapeutics for Alzheimer’s and other degenerative diseases, today announced financial results for the second quarter 2020 and provided an update on its business. “The participation of the medical community and patients in the GAIN study of atuzaginstat in mild to moderate Alzheimer’s disease continues to be strong, and we’re entering the final months of

Business Wire | August 17, 2020

Cortexyme Announces GAIN Trial of Atuzaginstat in Alzheimer’s Disease Has Reached Enrollment Milestone of 500 Patients

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cortexyme, Inc. (Nasdaq: CRTX) today announced that enrollment in its GAIN Trial for Alzheimer’s disease (AD) has reached 500 patients toward the study’s previously announced enrollment target of 570 subjects. GAIN is a randomized, double-blind, placebo-controlled Phase 2/3 trial of atuzaginstat (COR388), Cortexyme’s lead investigational medicine, in patients with mild to moderate AD. The GAIN Trial’s protocol includes an interim analysis on the stu

Business Wire | August 14, 2020

Cortexyme Announces Webcasts of Investor Conference Presentations in August 2020

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering potential therapeutics for Alzheimer’s and other degenerative diseases, today announced Casey Lynch, the company’s chief executive officer, chair, and co-founder, will present at the following two investor conferences in August 2020: The Canaccord Genuity 40th Annual Growth Conference: Ms. Lynch’s presentation will start at 2:00 p.m. EDT / 11:00 a.m. PDT on Wednesd

Business Wire | August 6, 2020

Read More 'CRTX' Stories Here

CRTX Price Returns

1-mo 1.08%
3-mo 14.30%
6-mo 9.02%
1-year 116.93%
3-year N/A
5-year N/A
YTD -13.02%
2019 N/A
2018 N/A
2017 N/A
2016 N/A
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.6124 seconds.